Immunic Conferences on Innovative Drug Development
Immunic, Inc. (Nasdaq: IMUX), a leading biotechnology company, is set to take part in an array of significant scientific and investor conferences this March. With a focus on developing a clinical pipeline for chronic inflammatory and autoimmune diseases, Immunic is excited to share insights about its innovative therapies that target some of the most pressing health challenges today.
Participating in Key Scientific Gatherings
March marks an essential month for Immunic as it lays out its participation in notable scientific conferences. From engaging in rigorous discussions to presenting groundbreaking research, these events offer opportunities for various stakeholders to understand the company's advancements.
34th Annual Meeting of the Society for Virology
From March 4-7, Immunic will feature prominently at the 34th Annual Meeting of the Society for Virology. Here, two pioneering abstracts from Immunic are set to be presented. These presentations will delve into Immunic’s distinctive approaches to antiviral therapies, showcasing cutting-edge research in the realm of virology.
Highlighted Presentations
- Title: Orally Bioavailable ROR?/DHODH Dual Host-Targeting Small Molecules with Broad-Spectrum Antiviral Activity
Presenting Author: Friedrich Hahn, Ph.D., from the Institute for Clinical and Molecular Virology in Germany.
Date: March 6, 2025, at 9:30 am CET. - Title: Novel Vidofludimus-Based DHODH Inhibitors with Enhanced Broad-Spectrum Antiviral Activity
Presenting Author: Alexandra Herrmann, Ph.D., Manager of Translational Pharmacology at Immunic.
Date: March 7, 2025, at 11:00 am CET.
Engaging with Investors
In addition to scientific conferences, Immunic will also participate in the Leerink Partners Global Healthcare Conference from March 10-12. The company’s Chief Executive Officer, Daniel Vitt, will engage in a fireside chat on March 12, providing insights into Immunic’s operational strategies and future developments.
Investors' Engagement
During the Leerink Partners conference, Dr. Vitt, alongside CFO Glenn Whaley and VP of Investor Relations Jessica Breu, will conduct one-on-one meetings with investors. This approach underscores Immunic’s commitment to transparency and open dialogue with its stakeholders.
About Immunic, Inc.
Immunic, Inc. is at the forefront of biotechnology innovation. With a dedicated focus on developing oral therapies aimed at chronic diseases, the company has made significant strides with its lead product, vidofludimus calcium (IMU-838), currently undergoing pivotal clinical trials for multiple sclerosis. Through its pioneering efforts, Immunic combines neuroprotective properties and antiviral activity, providing new hope for patients with chronic inflammatory conditions.
Future Directions
Immunic continues to push boundaries with therapies like IMU-856, targeting gastrointestinal diseases, and the innovative IMU-381 aimed at enhancing gut health. As industry trends evolve and challenges arise, Immunic remains dedicated to developing solutions that address unmet medical needs.
Frequently Asked Questions
What conferences is Immunic participating in this March?
Immunic is participating in the 34th Annual Meeting of the Society for Virology and the Leerink Partners Global Healthcare Conference.
Who will be presenting at the Society for Virology?
Friedrich Hahn, Ph.D. and Alexandra Herrmann, Ph.D. will be presenting Immunic's research during the conference.
What is the focus of Immunic's presentations?
The presentations will focus on innovative antiviral therapies and their applications in treating autoimmune diseases.
When is Daniel Vitt speaking at the Leerink Partners conference?
Daniel Vitt will participate in a fireside chat on March 12, during the conference.
What are the main products being developed by Immunic?
Immunic is developing several treatments, including vidofludimus calcium (IMU-838) for multiple sclerosis and IMU-856 for gastrointestinal diseases.
